PRNewsWire
25 Jun 2026, 23:36 UTC · 19w ago
Impact · against what's priced in
NovoCure faces significant downward pressure following a Phase 3 trial failure and a subsequent class-action investigation. Certara and Domo face minor idiosyncratic risk due to separate legal investigations mentioned in the same release.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
NovoCure's Phase 3 TRIDENT trial failed to show a statistically significant improvement in overall survival for the Early Start Arm compared to the Maintenance Start Arm.
So whatFailure of a primary endpoint in a Phase 3 clinical trial for a core product typically leads to significant valuation loss and limits future market expansion.
More negative than 98% of claims this week
Pomerantz LLP is investigating potential securities fraud and unlawful business practices by NovoCure and its officers following the trial results.
Continue reading
5 related stories
The failure of the Phase 3 TRIDENT trial's primary endpoint and the resulting 20% price drop are coupled with a new securities fraud investigation by Pomerantz LLP.
Read from the article alone
No priced-in read yet
Pomerantz LLP has launched an investigation into potential securities fraud or unlawful business practices at Certara.
Read from the article alone
No priced-in read yet
Pomerantz LLP is investigating whether Domo and its officers engaged in securities fraud or other unlawful business practices.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 83% of claims this week
NovoCure's stock price declined 20% to $14.28 on June 18, 2026, immediately following the trial result announcement.
More negative than 67% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The company is facing a class action investigation following a trial failure that caused a 20% drop in stock price.
More negative than 83% of ticker scores this week
The company is being investigated by the Pomerantz Law Firm on behalf of investors.
More negative than 83% of ticker scores this week
The company is being investigated by the Pomerantz Law Firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
−19.9%
Price agrees with the score
$12.06 vs $15.05 close before publication (Jun 25) · not market-adjusted
NVCR chart →+45.5%
Price is moving against the score
$3.55 vs $2.44 close before publication (Jun 25) · not market-adjusted
DOMO chart →+118.9%
Price is moving against the score
$12.02 vs $5.49 close before publication (Jun 25) · not market-adjusted
CERT chart →
